TNXP vs. DRUG

Last updated Apr 2, 2026

Compare and contrast key facts about Tonix Pharmaceuticals Holding Corp. (TNXP) and Bright Minds Biosciences Inc (DRUG).

Performance

TNXP vs. DRUG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tonix Pharmaceuticals Holding Corp. (TNXP) and Bright Minds Biosciences Inc (DRUG). The values are adjusted to include any dividend payments, if applicable.

TNXP vs. DRUG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TNXP Tonix Pharmaceuticals Holding Corp.	-12.42%	-52.64%	-97.44%	-83.46%	-96.59%	-75.99%
DRUG Bright Minds Biosciences Inc	-8.10%	116.66%	2,418.88%	-61.35%	-76.66%	-41.30%

Fundamentals

Market Cap TNXP : $116.43M DRUG : $556.64M
EPS TNXP : -$9.34 DRUG : -$2.55
PB Ratio TNXP : 0.47 DRUG : 6.23
Total Revenue (TTM) TNXP : $13.11M DRUG : $0.00
Gross Profit (TTM) TNXP : $6.47M DRUG : -$43.62K
EBITDA (TTM) TNXP : -$123.98M DRUG : -$13.97M

Returns By Period

In the year-to-date period, TNXP achieves a -12.42% return, which is significantly lower than DRUG's -8.10% return.

TNXP

• 1D: -0.51%
• 1M: -2.15%
• YTD: -12.42%
• 6M: -42.88%
• 1Y: -21.60%
• 3Y*: -89.50%
• 5Y*: -88.81%
• 10Y*: -84.40%

DRUG

• 1D: -1.71%
• 1M: -13.39%
• YTD: -8.10%
• 6M: 23.76%
• 1Y: 98.62%
• 3Y*: 219.43%
• 5Y*: 21.80%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TNXP vs. DRUG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TNXP

TNXP Risk / Return Rank: 34
TNXP Sharpe Ratio Rank: 30
TNXP Sortino Ratio Rank: 39
TNXP Omega Ratio Rank: 37
TNXP Calmar Ratio Rank: 31
TNXP Martin Ratio Rank: 34

DRUG

DRUG Risk / Return Rank: 80
DRUG Sharpe Ratio Rank: 80
DRUG Sortino Ratio Rank: 82
DRUG Omega Ratio Rank: 73
DRUG Calmar Ratio Rank: 83
DRUG Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TNXP vs. DRUG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tonix Pharmaceuticals Holding Corp. (TNXP) and Bright Minds Biosciences Inc (DRUG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TNXP	DRUG	Difference
Sharpe ratio Return per unit of total volatility	-0.22	1.34	-1.55
Sortino ratio Return per unit of downside risk	0.39	2.24	-1.84
Omega ratio Gain probability vs. loss probability	1.04	1.24	-0.20
Calmar ratio Return relative to maximum drawdown	-0.29	2.78	-3.07
Martin ratio Return relative to average drawdown	-0.43	6.19	-6.61
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TNXP vs. DRUG - Sharpe Ratio Comparison

The current TNXP Sharpe Ratio is -0.22, which is lower than the DRUG Sharpe Ratio of 1.34. The chart below compares the historical Sharpe Ratios of TNXP and DRUG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TNXP	DRUG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.22	1.34	-1.55
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.66	0.03	-0.69
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.60	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.58	0.03	-0.61

Correlation

The correlation between TNXP and DRUG is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TNXP vs. DRUG - Dividend Comparison

Neither TNXP nor DRUG has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

TNXP vs. DRUG - Drawdown Comparison

The maximum TNXP drawdown since its inception was -100.00%, roughly equal to the maximum DRUG drawdown of -97.68%. Use the drawdown chart below to compare losses from any high point for TNXP and DRUG.

Drawdown Indicators

	TNXP	DRUG	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	-97.68%	-2.32%
Max Drawdown (1Y) Largest decline over 1 year	-80.46%	-34.10%	-46.36%
Max Drawdown (5Y) Largest decline over 5 years	-100.00%	-97.68%	-2.32%
Max Drawdown (10Y) Largest decline over 10 years	-100.00%	—	—
Current Drawdown Current decline from peak	-100.00%	-25.28%	-74.72%
Average Drawdown Average peak-to-trough decline	-91.05%	-60.63%	-30.42%
Ulcer Index Depth and duration of drawdowns from previous peaks	55.09%	15.97%	+39.12%

Volatility

TNXP vs. DRUG - Volatility Comparison

Tonix Pharmaceuticals Holding Corp. (TNXP) has a higher volatility of 27.68% compared to Bright Minds Biosciences Inc (DRUG) at 13.61%. This indicates that TNXP's price experiences larger fluctuations and is considered to be riskier than DRUG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TNXP	DRUG	Difference
Volatility (1M) Calculated over the trailing 1-month period	27.68%	13.61%	+14.07%
Volatility (6M) Calculated over the trailing 6-month period	51.40%	49.40%	+2.00%
Volatility (1Y) Calculated over the trailing 1-year period	99.65%	74.18%	+25.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	135.80%	662.78%	-526.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	141.06%	660.68%	-519.62%

Financials